Clarkston Consulting Accepting Applications for $10K Clarkston Scholars Award in partnership with Pennsylvania Bio
Applications for $10,000 Clarkston Scholars Award now being accepted from eligible undergraduate students focusing in a Life Sciences related field of study.
Horizon Discovery Announces £11.3 Million ($18.6 Million) Fundraising
Senior management team and board of directors strengthened with key appointments.
Cancer Genetics Appoints Elizabeth A. Czerepak as Chief Financial Officer
Ms. Czerepak will lead the finance, clinical billing operations, human resources, and administrative support functions.
VAXIMM Closes a CHF 7.8 Million Financing Round
Company plans to use the proceeds of the financing to progress its lead program VXM01 into and through clinical phase I testing.
Whole Genome Sequencing used to Help Inform Cancer Therapy
Physicians and researchers at Mayo Clinic in Arizona and the Translational Genomics Research Institute (TGen) have successfully completed sequencing both a single patients normal and cancer cells - more than 6 billion DNA chemical bases.
Everist Genomics Announces External Validation of OncoDefender™-CRC Colorectal Cancer Recurrence Test
New data presented at the ASCO-GI Cancers Symposium demonstrate potential for optimizing clinical management of early stage colon and rectal cancers.
SCI Installs First TomoTherapy® Radiation Therapy System in Seattle Metropolitan Area
Introduction of TomoTherapy Treatments at New Ballard, Wash. facility delivers flexibility in treating wide range of Cancers.
GE Healthcare Presents Flutemetamol Data for Detection of Amyloid Plaque Linked to Alzheimer's Disease
Five Flutemetamol abstracts to be featured at the 2011 Human Amyloid Imaging Meeting in Miami.
Allon Enrolling Patients in Pivotal Davunetide Phase 2/3 Trial
Allon Therapeutics Inc. has announced that it has initiated a pivotal Phase 2/3 clinical trial to evaluate the Company's neuroprotective drug candidate, davunetide, as a potential treatment for progressive supranuclear palsy (PSP), a rapidly-progressing and fatal degenerative brain disease.
TauRx Granted European Composition of Matter Patent for Lead Compound in Treatment and Prevention of Neurodegenerative Diseases Including Alzheimer’s Disease
LMTX, poised to enter phase III, in development as a potential neurodegeneration disease modifying agent with a patent life extending to 2027.